CANF (Can Fite Biopharma) Valuation Rank


CANF Can Fite Biopharma Ltd CANF
60 GF Score
Price $2.99
GF Value $5.98
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Can Fite Biopharma Valuation Rank Related Terms

CANF
60GF Score
Can Fite Biopharma Ltd CANF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98. GuruFocus considers Can Fite Biopharma to be Possible Value Trap.

Key valuation signals for CANF:

  • Valuation Rank:
  • GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score

Get the complete analysis for CANF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.99
Price
$5.98
GF Value